Human medicines European public assessment report (EPAR): Aquipta, atogepant, Migraine Disorders, Date of authorisation: 11/08/2023, Status: Authorised

Apomorphine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00000227/202211

Apomorphine : List of nationally authorised medicinal products - PSUSA/00000227/202211

Human medicines European public assessment report (EPAR): Regkirona, regdanvimab, COVID-19 virus infection, Date of authorisation: 12/11/2021, Revision: 8, Status: Authorised

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), Online, 13:00 - 14:00 Amsterdam time (CEST), from 14/07/2023 to 14/07/2023

Opinion/decision on a Paediatric investigation plan (PIP): ritlecitinib, decision type: , therapeutic area: , PIP number: P/0333/2022

Opinion/decision on a Paediatric investigation plan (PIP): tezepelumab, decision type: , therapeutic area: , PIP number: P/0355/2022

Opinion/decision on a Paediatric investigation plan (PIP): Vibegron, decision type: , therapeutic area: , PIP number: P/0288/2022

Opinion/decision on a Paediatric investigation plan (PIP): RoActemra,tocilizumab, decision type: , therapeutic area: , PIP number: P/0354/2022

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Hypertension, Date of authorisation: 13/03/2013, Revision: 11, Status: Authorised